Austin-based LDR Holding Corporation announced that the Current Procedural Terminology (CPT) Editorial Panel has accepted the addition of Category I code 22858X to support two-level cervical arthroplasty procedures with Mobi-C® Cervical Disc. The change of the code was disclosed on the website of the American Medical Association (AMA) and will be effective from January 1, 2015. This indicates that the Category III code 0092T will be eliminated.
The coding change was significant in order to properly accommodate the novel technology behind the Mobi-C, which is a cobalt chromium alloy and polyethylene, mobile-bearing prosthesis. The device, according to a company press release, “is specifically designed as a bone-sparing, cervical intervertebral disc replacement for both one and two-level indications.” A major feature of the new device is not only its mobile-bearing ability, but also the simplified surgical technique for implementing it. Comparable devices on the market today, all of which have been approved by the U.S. Food and Drug Administration, are for one-level use only, making Mobi-C a particularly viable two-level option for surgeons.
LDR Holding Corporation is a global medical device company developing surgical technologies for the treatment of patients with spine disorders. Their product Mobi-C(R) is the first and the only cervical disc replacement device received FDA-approval for the treatment of both one-level and two-level cervical disc disease.
“This coding change is a significant milestone in the field of cervical disc replacement. While two-level arthroplasty procedures are being performed today, beginning in 2015, they will have the full coding and payment structure necessary to provide patients access to this very important procedure,” said Christophe Lavigne, President and CEO of LDR. “We are very pleased that the North American Spine Society supported the application consistent with their efforts in advocating for evidence-based medicine and fair coding and reimbursement decisions. We feel that this is another important step in the process to provide broad availability to this beneficial treatment option to patients suffering from two-level cervical disc disease.”